Kevin C. Reyes

Associate
San Diego
  • 12670 High Bluff Drive
  • San Diego, CA 92130
  • USA
Profile Experience

Kevin Reyes has a general corporate transactional practice, representing both private and public companies in a wide variety of corporate matters.

His practice includes:

  • General corporate matters
  • Mergers and acquisitions
  • Corporate governance
  • Public offerings
  • Emerging companies
  • Venture capital financing

While attending the University of Southern California Gould School of Law, Mr. Reyes published a student note for the Southern California Interdisciplinary Law Journal, and served as a teaching fellow for the Legal Writing and Advocacy Program. During law school, he also served as a judicial extern for Judge Virginia A. Phillips in the US District Court for the Central District of California.

Mr. Reyes has advised on a broad range of corporate transactions, including numerous public and private company mergers, acquisitions, asset sales, investments, and venture capital fund raisings.

Significant matters include representing:

  • Agility Clinical in its sale to Precision Medical Group for proceeds of up to US$46 million
  • Alphatec Spine in the US$80 million sale of its international business to Globus Medical
  • Aratana Therapeutics’ €33.3 million stock acquisition of Okapi Sciences and US$30 million cash and stock merger with Vet Therapeutics
  • BioMed Realty Trust in its US$8 billion acquisition by affiliates of The Blackstone Group
  • Callaway Golf Company in its US$75 million acquisition of Ogio International, US$125 million acquisition of TravisMathew, and €418 million acquisition of German-based Jack Wolfskin
  • Excel Trust in its US$2 billion acquisition by affiliates of The Blackstone Group
  • Extra Space Storage in its US$1.4 billion acquisition of SmartStop Self Storage
  • Impact Biomedicines in its acquisition by Celgene Corporation for up to US$7 billion
  • Ligand Pharmaceuticals in its US$178 million acquisition of Open Monoclonal Technology
  • Neurelis in its acquisition of Aegis Therapeutics
  • Pulse Electronics in a US$26 million going private transaction with Oaktree Capital Management
  • ViaSat in its US$62 million acquisition of NetNearU, a provider of network management systems for Wi-Fi and other internet access networks
  • Zavante Therapeutics, in its stock-for-stock sale to Nabriva Therapeutics plc for up to US$125 million  

Mr. Reyes has also advised numerous companies and underwriters on various public and private financings, including PIPE financings, venture financings, private equity and debt offerings, and initial, follow-on, and secondary public offerings including representing:

  • Airgain in its US$12 million initial public offering
  • Alphatec Spine in a US$18 million PIPE financing
  • Crinetics Pharmaceuticals in its US$117 million initial public offering
  • Essex Property Trust in senior notes offerings raising US$800 million
  • Exagen Diagnostics in its proposed initial public offering and in corporate governance matters
  • Extra Space Storage in equity and debt offerings raising more than US$875 million
  • Gossamer Bio in its US$317 million initial public offering
  • Neurelis in its preferred stock financings with LYZZ Capital, HBM Healthcare Investments, and China Medical Systems, raising over US$50 million
  • ViaSat in equity and debt offerings raising more than US$1 billion
  • Zavante Therapeutics in its Series A financing with Frazier Healthcare Partners, Longitude Capital, and Aisling Capital
  • ZipRecruiter in its US$63 million Series A financing led by Institutional Venture Partners
  • A number of investment banks, including Barclays, BofA Merrill Lynch, BMO, Jefferies, J.P. Morgan, Piper Jaffray, and Stifel, in public offerings of equity securities for life sciences companies, including initial public offerings for Applied Genetic Technologies Corporation, Glycomimetics, and Lumena Pharmaceuticals (prior to its sale), as well as public offerings for ACADIA Pharmaceuticals, Biocryst Pharmaceuticals, Clovis Oncology, Mirati Therapeutics, Neurocrine Biosciences, and Sarepta Therapeutics

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.